Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2016 February;64(1) > Minerva Cardioangiologica 2016 February;64(1):1-8





A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695




Minerva Cardioangiologica 2016 February;64(1):1-8


language: English

Effectiveness of a novel biodegradable polymer, sirolimus-eluting stent platform in percutaneous coronary intervention

Marcello DOMINICI 1, 2, Alessio ARRIVI 1, Marco BAZZUCCHI 1, Marcella DE PAOLIS 1, Caterina MILICI 1, Carlo BOCK 1, Attilio PLACANICA 1, Ludovico LAZZARI 1, Roberto DILETTI 2, 3, Enrico BOSCHETTI 1, 2

1 Interventional Cardiology Unit, S. Maria University Hospital, Terni, Italy; 2 University of Perugia/Terni School of Medicine, Terni, Italy; 3 Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands


BACKGROUND: The purpose of this registry is to report the immediate and long-term safety and efficacy of the Biotronik Orsiro stent in an unselected population during everyday practice.
METHODS: Between May 2012 and June 2013, 246 consecutive coronary angioplasty procedures were performed using at least one Orsiro drug-eluting stent, in 225 patients and 303 lesions.
RESULTS: Diabetes was present in 34.7% of patients. Procedures were non-elective percutaneous coronary intervention (PCI) in 17.1% of cases and acute coronary syndromes were 55.1%. Radial vascular access was used in 78% of cases, multivessel PCI was performed in 19.5% of the procedures. In 81.6% of cases lesions were B2/C type, 20.7% of procedures had bifurcation lesions. Procedural success was 99.6%. No acute thrombosis occurred. Clinical follow-up median period was 24.3 (±8.28) months and FU was available in 93.7% of patients. Death for any cause occurred in 11 patients (5.2%), 6 of them were non cardiac-related. Cardiac-related death rate was 2.4%. Two patients had in-stent restenosis. The overall target lesion failure rate was 3.3%.
CONCLUSIONS: This observational data regards our experience with Biotronik Orsiro stent in an unselected population. This initial data, although limited by a mainly clinical follow-up and restricted number of patients, confirms the good clinical performance of this sirolimus-eluting stent with a biodegradable polymer in everyday practice, including complex lesions, according to current larger studies in the literature.

top of page

Publication History

Cite this article as

Corresponding author e-mail